The Technical AnalystExchange: PNK Industry: Biotechnology
ProtoKinetix, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.71% $0.0156
America/New_York / 3 mai 2024 @ 15:14
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.40 mill |
| EPS: | -0.0100 |
| P/E: | -1.560 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 346.71 mill |
| Avg Daily Volume: | 0.101 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.560 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.560 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0001 (-99.61%) $-0.0155 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0126 - 0.0186 ( +/- 19.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Smith Clarence Edward | Buy | 2 500 000 | Common Stock |
| 2024-03-20 | Smith Clarence Edward | Buy | 666 667 | Common Stock |
| 2023-12-26 | Smith Clarence Edward | Buy | 7 333 334 | Common Stock |
| 2023-10-26 | Guzzetta Michael Richard | Buy | 20 000 | Common Stock |
| 2023-08-29 | Smith Clarence Edward | Buy | 1 500 000 | Common Stock |
| INSIDER POWER |
|---|
| 75.43 |
| Last 100 transactions |
| Buy: 250 709 791 | Sell: 135 159 880 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0156 (-7.71% ) |
| Volume | 0.417 mill |
| Avg. Vol. | 0.101 mill |
| % of Avg. Vol | 411.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PKTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PKTX
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.